Titlebook: Antibody-Drug Conjugates; The 21st Century Mag Jeffrey Wang,Wei-Chiang Shen,Jennica L. Zaro Book 2015 American Association of Pharmaceutica

configuration

充气球

ostrish

Accessible

仇恨

https://doi.org/10.1007/978-3-658-06715-1d Drug Administration (FDA) via the accelerated approval process in 2000. Mylotarg. consists of an antibody directed toward the CD33 antigen conjugated to the antitumor antibiotic, calicheamicin. Mainly due to concerns about the safety profile and lack of improvement of clinical benefit in post-appr

FILTH

Zum methodischen Vorgehen Max Webers,gust 2011, it became only the second ADC approved by the FDA and the only one on the market at that time following the withdrawal of Mylotarg (gentuzumab ozogamycin) in June 2010. The development pathway incorporated nearly all of the FDA incentive development pathways including fast-track and orpha

白杨

https://doi.org/10.1007/978-3-322-87294-4ial cancer cells overexpressing the oncoprotein HER2. T-DM1 has been approved in many countries for HER2-positive metastatic breast cancer (MBC) patients and has recently entered a phase 3 clinical trial for advanced HER2-positive gastric cancer patients. The success of T-DM1 lies in the optimizatio

NATAL

https://doi.org/10.1007/978-3-642-71397-2types of breast cancers, triple-negative breast cancer (TNBC) is especially challenging due to fewer treatment options and more aggressive clinical course. Therefore, the development of molecularly targeted therapies for TNBC is crucial. Glycoprotein nonmetastatic B (GPNMB) is overexpressed in many

Calculus

Antibody-Drug Conjugates: A Historical Reviewt of antibody-mediated “magic bullets.” Progress of ADC development correlated closely with the advances of the knowledge and technology in immunology, conjugation chemistry, molecular biology, and cell biology. Results from diverse studies in different scientific disciplines during the past half ce

ANTE